Related Experiment Video
Updated: Apr 30, 2026

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
Benmelstobart+anlotinib: an emerging therapeutic option in the targeted-immunotherapy era
Pan Cheng1, Hong Gu1, Qingqing Chen2
1Department of Pharmacy, Jingjiang People's Hospital Affiliated to Yangzhou University, Taizhou, China.
Abstract:
In recent years, with the gradual deepening of research, basic and clinical studies on targeted-immunotherapy combination regimens have flourished and yielded exciting results. The novel programmed cell death ligand 1 (PD-L1) inhibitor benmelstobart in combination with the targeted agent anlotinib demonstrates synergistic antitumor effects, achieving a synergy therapeutic outcome. This article focuses on the mechanisms underlying the combined action of "benmelstobart+anlotinib", summarizes the currently approved indications and clinical research progress, and aims to provide alternative therapeutic options for patients with malignant tumors as well as new insights for the development and selection of future combination treatment strategies.
Related Concept Videos
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against...
Targeted Cancer Therapies
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

